Summary
25.25 -0.60(-2.32%)07/05/2024
ARTIVION INC (AORT)
ARTIVION INC (AORT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.32 | 21.15 | 9.84 | 42.34 | 72.37 | 62.70 | 0.00 | 45.92 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.25 | |
| Open | 25.69 | |
| High | 25.83 | |
| Low | 24.44 | |
| Volume | 256,500 | |
| Change | -0.60 | |
| Change % | -2.32 | |
| Avg Volume (20 Days) | 202,135 | |
| Volume/Avg Volume (20 Days) Ratio | 1.27 | |
| 52 Week Range | 12.16 - 25.51 | |
| Price vs 52 Week High | -1.02% | |
| Price vs 52 Week Low | 107.65% | |
| Range | 3.80 | |
| Gap Up/Down | 1.52 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,055 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
07/03 08:00 EST - investorplace.com
3 Earnings All-Stars With More Room to Run
Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.
3 Earnings All-Stars With More Room to Run
Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.
07/01 16:05 EST - prnewswire.com
Artivion Amends Agreements with Endospan
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS").
Artivion Amends Agreements with Endospan
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS").
06/21 17:01 EST - seekingalpha.com
Data-Driven Growth Fuels More Upside For Overlooked Artivion
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.
Data-Driven Growth Fuels More Upside For Overlooked Artivion
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.
05/08 10:17 EST - zacks.com
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
05/06 22:47 EST - seekingalpha.com
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call.
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call.
05/06 18:21 EST - zacks.com
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
05/06 16:05 EST - prnewswire.com
Artivion Reports First Quarter 2024 Financial Results
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint ATLANTA , May 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024. "We are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities.
Artivion Reports First Quarter 2024 Financial Results
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint ATLANTA , May 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024. "We are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities.
04/29 08:05 EST - prnewswire.com
Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA , April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting in Toronto, Canada. Presentations highlighted 5-year real-world safety and efficacy data from the On-X Aortic Heart Valve Low INR post-market study that demonstrate even better patient outcomes than predicted by the On-X Aortic Heart Valve PROACT IDE Study, as well as Late-Breaking data from the AMDS PERSEVERE Trial demonstrating, at 30-days post-AMDS implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry (DANE) tears.
Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA , April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting in Toronto, Canada. Presentations highlighted 5-year real-world safety and efficacy data from the On-X Aortic Heart Valve Low INR post-market study that demonstrate even better patient outcomes than predicted by the On-X Aortic Heart Valve PROACT IDE Study, as well as Late-Breaking data from the AMDS PERSEVERE Trial demonstrating, at 30-days post-AMDS implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry (DANE) tears.
04/22 16:10 EST - prnewswire.com
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
04/15 10:46 EST - zacks.com
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
04/01 16:10 EST - prnewswire.com
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 10:15 a.m.
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 10:15 a.m.
03/29 10:16 EST - zacks.com
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
03/28 10:46 EST - zacks.com
Are Medical Stocks Lagging Artivion (AORT) This Year?
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Artivion (AORT) This Year?
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
03/19 17:31 EST - zacks.com
3 Buy-Rated Small Caps Flexing Big Growth
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
3 Buy-Rated Small Caps Flexing Big Growth
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
03/14 10:51 EST - zacks.com
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
03/12 10:46 EST - zacks.com
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
03/06 16:10 EST - prnewswire.com
Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m.
Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m.
02/21 10:56 EST - zacks.com
Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.